Fatty-acid oxidation disorders

The fellowship mark goes to the candidate who thinks in three layers simultaneously. The first is the child in front of you: a hypoglycaemic, encephalopathic infant after a viral illness, or an adolescent with exercise-induced muscle pain and dark urine. The immediate question is not which enzyme is defective but whether the child can make ketones. The second is the physiology: fasting triggers lipolysis, fatty acids enter the mitochondrion via the carnitine shuttle, and beta-oxidation trims two carbons at a time to generate acetyl-CoA, ketone bodies and ATP. A block anywhere in this chain produces an energy deficit and, in the long-chain defects, toxic accumulation. The third is the family: these are autosomal recessive conditions, newborn screening detects most of them, and a well-constructed sick-day plan is what keeps the child safe between episodes. [1] [4]

Overview & Definition

The fatty-acid oxidation disorders are a group of inherited metabolic diseases caused by defects in the transport of fatty acids into the mitochondrion or in their subsequent beta-oxidation to generate energy. The pathway begins with the carnitine shuttle — carnitine palmitoyltransferase I (CPT I), the carnitine-acylcarnitine translocase (CACT), and carnitine palmitoyltransferase II (CPT II) — which ferries long-chain fatty acids across the impermeable inner mitochondrial membrane. Once inside, the beta-oxidation spiral progressively shortens the fatty-acyl chain through a repeating cycle of dehydrogenation, hydration, dehydrogenation and thiolysis, with each enzyme class acting on a different chain-length range: very long-chain acyl-CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD, part of the mitochondrial trifunctional protein), medium-chain acyl-CoA dehydrogenase (MCAD), and short-chain acyl-CoA dehydrogenase (SCAD). [1] [4]

Clinically, the fatty-acid oxidation disorders sit within the family of fasting-induced energy-failure inborn errors: conditions in which a blocked catabolic pathway prevents the body from using its largest energy reserve — stored fat — during periods of caloric deficit. This framing matters because it dictates both the presentation (crisis during fasting, infection or exercise) and the management (prevent catabolism, provide alternative fuel). Medium-chain acyl-CoA dehydrogenase deficiency is by far the most common, accounting for the majority of diagnosed cases, and it was the first condition for which newborn screening by tandem mass spectrometry demonstrated a clear outcome benefit. The long-chain defects (VLCAD, LCHAD, CPT I, CPT II, CACT) are individually rare but collectively important because they cause cardiomyopathy, liver dysfunction and rhabdomyolysis in addition to hypoglycaemia. [1] [7]